Over the Span of AD, Roles of Astrocytes and Microglia Change
Reactive astrocytes spell trouble for synapses, while microglial transform from protective to destructive as disease progresses.
6458 RESULTS
Sort By:
Reactive astrocytes spell trouble for synapses, while microglial transform from protective to destructive as disease progresses.
Fast Plaque Clearance with Little ARIA? So Teases Trontinemab at AD/PD 2024 TauRx Parses Subgroups to Make the Case for Methylene Blue Derivative, Again Therapeutic Contenders Target Hard-to-Reach Pockets of Tau Mouse Models and Markers for Cerebral Amylo
In London, researchers claimed that a monomer is the minimal structure required for tau strains. On the other hand, the sky seems the limit for the number of Aβ strains that form in an individual brain.
A trio of studies report that missense variants in SORL1 that disrupt its trafficking or dimerization are highly likely to cause Alzheimer's disease in carriers, strengthening the case for SORL1 being a familial AD gene.
First papers from MoTrPAC initiative report myriad responses to endurance training in multiple organs in rats, including the brain and heart.
Increasingly, people must learn of their amyloid status and/or ApoE genotype in order to enter secondary prevention trials. At AAIC, researchers laid out their procedures to ethically break the news.
In some patients, the blood Aβ42/40 test fell too close to the cutoff for specialists to confidently diagnose AD. Comorbidities, drugs also complicate results. Two CSF tests are FDA-approved.
Two studies describe how small peptides that latch onto tau have an outsize impact on fibrillization of the protein. Both point to therapeutic strategies.
Two interference screens netted a thousand proteins that affect tau oligomerization. The affected pathways? Mitochondrial malfunction, and UFMylation.
Queen Sylvia of Sweden traveled to Gothenburg to welcome scientists to AD/PD. At the conference, the buzz was on about approaches to double levels of the lysosomal protein in FTD.
Lilly’s Phase 3 antibody remternetug resembles donanemab, but without pesky antidrug antibodies; Prothena’s Phase 1 PRX012 may need fewer injections.
PET tracers for the two main proteopathies of FTD, tau and TDP-43, are now in trials, while AI-enabled analysis of FDG-PET scans discriminates between diseases.
FDA qualification would streamline the use of plasma NfL to select asymptomatic carriers of pathogenic frontotemporal dementia mutations for enrollment in prevention trials.
People who sifted through piles of debris are nine times likelier to develop early onset, all-cause dementia than those exposed to little toxic dust.
Injected into the cerebrospinal fluid, a viral vector delivers the lysosomal protein into the human brain. In mice, a protein transport vehicle delivered into the blood does the same.
No filters selected